{
    "root": "2f352d7e-2d41-7222-e063-6294a90ad8d9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Doxepin hydrochloride",
    "value": "20250228",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSPOVIDONE (35 .MU.M)",
            "code": "40UAA97IT9"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 102",
            "code": "PNR0YF693Y"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "DOXEPIN HYDROCHLORIDE",
            "code": "3U9A0FE9N5"
        }
    ],
    "indications": "doxepin tablets indicated treatment insomnia characterized difficulty sleep maintenance . trials performed support efficacy 3 months duration .",
    "contraindications": "dose doxepin tablets individualized .",
    "warningsAndPrecautions": "doxepin 6 mg tablets oval shaped , light yellow , identified debossed markings \u201c 135 \u201d one side \u201c \u201d side , supplied : ndc : 70518-4297-00 ndc : 70518-4297-01 packaging : 30 1 box packaging : 1 1 pouch store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . protect light . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "hypersensitivity doxepin hydrochloride , inactive ingredients , dibenzoxepines . ( 4.1 ) co-administration monoamine oxidase inhibitors ( maois ) : administer patient taking maois used maois within past two weeks . ( 4.2 ) untreated narrow angle glaucoma severe urinary retention . ( 4.3 )",
    "indications_original": "Doxepin tablets are indicated for the treatment of insomnia characterized by difficulty with\u00a0sleep maintenance. The clinical trials performed in support of efficacy were up to 3 months\u00a0in duration.",
    "contraindications_original": "The dose of doxepin tablets should be individualized.",
    "warningsAndPrecautions_original": "Doxepin 6 mg tablets are oval shaped, light yellow, identified with debossed markings of \u201c135\u201d on one side and \u201cm\u201d on the other side, and are supplied as:\n                  \n                  NDC: 70518-4297-00\n                  NDC: 70518-4297-01\n                  PACKAGING: 30 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted between 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature]. Protect from light.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Hypersensitivity to doxepin hydrochloride, inactive ingredients, or other dibenzoxepines. ( 4.1 ) Co-administration with Monoamine Oxidase Inhibitors (MAOIs): Do not administer if patient is taking MAOIs or has used MAOIs within the past two weeks. ( 4.2 ) Untreated narrow angle glaucoma or severe urinary retention. ( 4.3 )"
}